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Our study of the aging process in human beings and in 
mice is complicated by our need to know whether we are 
observing diseases of aging or natural nondisease state 
processes. Results from studies on inbred strains of mice 
and retrospective studies on HLA types in aging human 
populations suggest that genetic effects play a signifi-
cant role in predetermining the life span of an individual. 
It is clear that in such mouse strains genetic defects that 
affect cell regulatory mechanisms result in the produc-
tion of autoimmune reactivity, tumor development, and 
a shortened life span. In human beings, although results 
are less clear-cut, strong associations exist between 
some disease states and the HLA type. Also, the disap-
pearance of HLA-B8 from older women suggests that 
this HLA type does not confer longevity. Cellular im-
mune reactivity declines with age in all populations 
studied to date, and cell cooperative or regulatory mech-
anisms function less well. We need to characterize the 
specific nature of the cells directly responsible for these 
alterations and to attempt to correct deficiencies by 
dietary manipulation or transfer techniques. 
The term "aging," which is normally used only in reference 
to long-lived members of the population under study, can be 
defined as a genetically programmed, slow decline in the fun c-
tional effectiveness of the organism that leads to death. "Life 
span" is the duration of the life of an individual. For a popula-
tion, the life span is calculated by the median duration of life or 
the duration of life of the longest survivors. Aging comprises 
the collective changes that occur over th e course of a life span 
and that limit the life span. There is a great deal of evidence 
that both genetic and environmental factors influence life span 
and aging [1]. 
Current knowledge suggests that the development of age-
associated diseases and physiological changes may in part be 
promoted by the immunity system. In studies on the etiology 
and genesis of age-associated disease or dysfunction, 2 factors 
stand out: (a) thymic involution accompanied by cell-mediated 
immune dysfunction and (b) major-histocompatibility-com-
plex-associated genetic control of the immunologic response 
and of resistance to disease. Deficiencies in immune function 
have not yet been shown to be fundamental to the production 
of such age-associated disease states as autoimmunity; vascular 
degeneration and insufficiency; and kidney and central nervous 
system degeneration . Most studies have been limited to corre-
lation between deficiencies occurring with age and diseases of 
aging. We do not know whether the changes in the immunity 
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system that occur with age are responsible for the decline in 
functional effectiveness or whether aging produces secondary 
immunologic changes. The purpose of this article is to review 
the general topics that should be considered in any discussion 
of immunology and aging. We will briefly discuss some previ-
ously unpublished data to illustrate the pitfalls of studying the 
human immunity system in genera l and particularly in rela tion 
to age-associated change. 
Generally, few argue with the inclusion, as parts of the aging 
process, of conditions such as graying of the hair and wrinkling 
of the skin or with the exclusion of embryogenesis and processes 
involved in biological maturation. However, the aging and death 
of organisms or individual cells may occur at any stage of 
development. Organs develop and involute according to a spe-
cific timetable within a particular genetic framework . The time-
table of organ development and involution in a given species 
and the limits imposed by a preordained proliferative capacity 
of cells after birth strongly suggest that the life span itself can 
be considered to be under complex genetic control mediated 
through cellular and organ "clocks." However, because the life 
span is also the result of adaptations to the environment, it is 
not possible to exclude stochastic theories from explanations of 
the aging process [1,2]. 
Through medicine, sanitation, and nutrition, people have 
manipulated their environments in a manner that effects SUl' -
viva!. In recent decades such manipulation has led to survival 
curves progressively approaching a rectangular shape. Conse-
quently, at approximately 80 to 85 yr of age, the remaining 
population (5 to 8% of the original cohort) are among those 
individuals of maximum genetically determined life span. This 
is the most appropriate group for study of aging [3]. It is known 
that approximately 20% of the general population have genetic 
defects that shorten their life spans and contribute to the 
mortality of persons below 70 yr of age [1]. These observations 
emphasize how difficult it is to separate reseal'ch on aging from 
research on diseases of aging. They also argue in a general sense 
in favor of the existence of genetically determined physiological 
and cellular clocks. Our task in the future will be to assess the 
number of such clocks that playa crucial role in determining 
the maximal life span of an individual or a species. Our disclls-
sion will focus on what might be called the thymus clock. 
IMMUNITY AND AGING 
Both humoral and cell-mediated immunologic responses de-
cline with age in all animals. In mice, optimal humoral immu-
nologic activity is observed early in life, at about 14% of the 
mean life span. The activity then declines gradually and in later 
life the animals have only 5 to 10% of their peak activity [4]. 
This decrease is found in both primary and secondary responses 
to antigens that require thymic influence to elicit an immuno-
logic response as well as to those that do not require thymic 
influence [4,5]. In older humans the heteroantibody and isoan-
tibody serum levels are relatively lower [5,6]. 
It appears that the decline in immune function that accom-
panies aging is due mainly to changes in the populations of 
thymus-derived cells (T cells) in the lymphoid organs and in 
the peripheral blood. One might expect the number of circulat-
ing lymphocytes, as well as the relative number of T lympho-
cytes, to decrease progressively after 60 years of age, but we did 
not find any significant decrease in these values up to the age 
of 100 years [7]. However, even if a decrease in lymphocytes 
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does occur, the changes might not be sufficient to account for 
the alterations in immunologic phenomena that occur after 80 
yr of age [7]. A partial catalogue of functional studies in humans 
(Table I) and in 2 strains of mice with dramatically different 
life spans (Table II) shows that parameters associated with 
cellular immunity, and particularly T-cell function, decrease 
even when the percentage of peripheral T cells remains normal. 
The level of humoral immunity, as defined by the measured 
immunologic response to a selected antigen, is usually lowei' 
among aged persons. In mice, the number of antibody-forming 
cells after injection of a standard heterologous antigen, such as 
sheep erythrocytes, is lower than in control mice. One must 
keep in mind, however, that most humoral immunity is regu-
lated by T cells. This complication, plus the normal or increased 
levels of serum immunoglobulins in the aged, make us reluctant 
to ascribe any age-associated change in humoral immunity to 
a general decline in the function of bone-marrow-derived cells 
(l? cells). 
'In both animals and humans a progressive decrease in the 
mass of the lymphoid system generally begins after puberty 
and continues throughout adult life. Under normal circum-
stances, a fairly good correlation exists between lymphoid mass 
and immune function. Thymic involution precedes and is prob-
ably the key determinant of the age-dependent decline in the 
ability of the immunity system to generate functional T cells. 
The alteration appeal'S to reside in a T-cell differentiation 
pathway. Changes observed in the thymus during aging include 
a decrease in the relative size of the thymic cortex and an 
increase in the number of macro phages. The medulla generally 
becomes infiltrated with plasma cells and mast cells. The num-
ber of secretory epithelial cells, particulal'ly those of the cortex, 
decreases with age. Functionally, the progressive decline in 
thymic influence on T-cell differentiation results in a deficient 
lymphocyte population of T -cell-dependent areas of the lymph 
nodes and a decline in T-cell function. 
TABLE 1. Alteration. of immunity param.eters in. aging p eople 
Cellular immunity 
Response to phytohemagglutinin 
Response to concanavalin A 
Response to allogeneic ce Lis 
Suppressive action of concanavalin-
A-stimulated lymphocytes 
Percentage of peripheral T cells 
Humoral immunity 
Antibody response to heterologous 
antigens and isoantigens 
Autoantibody production 
Serum levels of IgG and IgA 
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Experiments with mice have shown that 3 factors determine 
the magnitude of immunologic activity in the aged: the thymus, 
the bone marrow, and the humoral environment of the lym-
phoid cells. Of these, the thymus seems to be the limiting factor 
for immunologic vigor in the aged mouse. The immunologic 
capacity of an aged animal can be reconstituted by transplan-
tation of young thymus, plus young bone marrow [8]. 
The decline in immune function reflects a decrease in the 
number of the cells, a decrease in their function, and an alter-
nation of the environment in which they function. Approxi-
mately 10% of the decline in inlmune function has been attrib-
uted to environmental factors (extrinsic to the cells). The other 
90% of the reduction in immune vigor in the aged, as measured 
by antibody-forming capacity, appears to be the consequence 
of changes in the cells. In addition, immunologic abnormalities 
may be related to changes in the distribution of different subsets 
of lymphocytes (ecotaxopathy). However, a ny statement re-
garding "proportions" of immunologic capacity is only valid in 
the context of the antigens utilized and the experimental assays 
performed. 
THYMUS INVOLUTION IN SHORT-LIVED STRAINS 
OF MICE 
Decline in thymic size followed by deficiencies in cell-me-
diated immune functions occurs earlier in some individuals and 
in some inbred mouse strains than in others. The immunodefi-
ciency that occurs in some inbred strains relatively early in life, 
e.g., during the 2nd year for A strain mice, is strikingly similar 
to that produced by neonatal thymectomy [9,10]. Lymphoid 
neoplasms and lung tumors occur in young mice whose life span 
has been reduced by irradiation [11]. Thymic involution comes 
relatively late in CBA mice. This strain usually tends to be very 
long-lived and to maintain immune function longer than many 
other strains. 
AUTOIMMUNE STRAINS OF MICE 
In 1963, it was found that N ew Zealand black (NZB) mice 
regularly showed spontaneous development of autoimmune 
hemolytic anemia and positive Coombs' test results. Antinu-
clear antibodies and immune complex glomerular disease were 
found to develop in these mice as well as in NZBx NZW F, 
hybrids. Neonatal thymectomy shortens the incubation period 
of these diseases. Similarly, antinuclear antibodies develop 
spontaneously in A/J mice [9,12]. Neonatal thymectomy facil-
itates the development of this autoimmune disease and is 
accompanied by extraordinary plasma cell proliferation in the 
lymphoid tissues, a regular finding in aging mice of autoimmu-
nity-susceptible strains. In contrast, CBA/H and C3H mice, in 
which autoimmunity does not develop spontaneously with ag-
ing, exhibit lymphoid tissue atrophy and show much less evi-
dence of autoantibody production after neonatal thymectomy. 
The immunologic deficiencies, the autoimmune hemolytic ane-
mia, the antinuclear and anti-DNA antibodies, and the h ema-
TABLE II. Alteration ofim.nwn.e function.s in. selected short· lived and autoimm.unity·susceptible and lOllg- lived autoimm.unity-resistant 
strains of mice 
R esponse to mitogens ResisLance Lo 
Mice Cellular- immune Suppressor T cells allogeneic Age PHA LPS Antibody- function/} or t.hYlnic honnonc Lumor cells (mo) ('I' cell) (B ce ll) forming cells" 
NZB 2 Normal Normal High High Low High 
(autoimmunity-susceptible) 12 Low Low Low Low Low Low 
NZB x NZW F, 2 Normal Normal High Normal Low High 
(autoimmunity-susceptible) 10 Low Normal Low Low Low Low 
CBA/H 2 High High Normal Normal High High 
(autoimmunity-resistant) t2 High High Normal High Low High 
24 Low Normal Low Normal Low Normal 
" Sheep erythJ'ocytes_ 
/, Graft-versus-host reaction. 
Abbreviations: PHA = phytohemagglutinin; LPS = lipopolysaccharides; NZB = New Zealand black; NZW = New Zealand white. 
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tologic, hepatic, splenic, and renal lesions that appear early in 
life after neonatal thymectomy in autoimmunity-susceptible 
mice seem to reflect an acceleration of the processes associated 
with cellular immunodeficiency during aging in mice of these 
strains. 
Another line of evidence that links immunodeficiency with 
autoimmunity is demonstrated by efforts to correct immuno-
deficiencies in thymectomized animals. Both immunodeficiency 
and autoimmunity in neonatally t hymectomized mice can be 
prevented by transplantation of syngeneic or allogeneic thy-
muses from young mice, or by injection of thymus lymphocytes 
or spleen lymphocytes from syngeneic, semiallogeneic, or allo-
geneic donors [9,12]. To avoid a lethal graft-versus-host reac-
tion, one must match the thymus or peripheral lymphoid cells 
injected with the recipient at the major histocompatibility 
complex (MHC) [13]. The autoimmune diseases and immuno-
deficiencies of neonatally thymectomized mice may be reversed 
by treatment with multiple thymus grafts or injections of large 
numbers of t hymus cells or peripheral lymphoid cells even aft er 
t he wasting disease and autoimmune processes have appeared 
[12,13]. 
It has been shown that spleen cells from young A or NZB 
mice differentiate into antibody-producing cells in young recip-
ients. However, spleen cells from an older donor in a young 
irradiated recipient, or spleen cells from a young donor given to 
an old irradiatep recipient, do not generate plaque-forming cells 
very well. These findin gs are consistent with the view that the 
immunodeficiency of aging in a short-lived or autoimmunity-
susceptible strain involves both the lymphoid cells themselves 
and the environment in which they function [4]. 
GENETIC ASPECTS OF AGING: INFLUENCE OF THE 
MAJOR HISTOCOMPATIBILITY COMPLEX 
The immunodeficiency states (acquired or congenital) that 
have been observed in humans and animals at all ages are 
associated with th e production of autoimmunity and the devel-
opment of malignant tumors. Although these diseases are more 
prevalent in the aged, it is still uncertain whether they are 
diseases of aging or the result of a more basic genetic defect. 
One example of immunodeficiency of adult life in mice is the 
thymic deficiency and congenital viral infection in NZB mice; 
NZB hybrid mice live longer than the parent strain and have a 
concomitant correction of the thymic defect by the breeding 
manipulation. These facts do not prove that thymic involution 
causes a decreased life span, but they serve to emphasize the 
genetic influence on both longevity and thymic involution. 
We had suggested that because the MHC represents the 
main genetic regulator of the immune system, it should influ-
ence the life span [14]. The H-2 system of mice and the HLA 
system of human beings encode for antigen markers of genes 
that identify (a) the ability to mount a vigorous immunologic 
response to .a variety of antigens and (b) susceptibility to a 
variety of diseases. There is now a great deal of evidence that 
suggests mouse genes controlling the ability to respond immu-
nologically to a variety of naturally occurring and synthetic 
antigens within the MHC (H-2) between H-2K and the Ss-slp 
locus [15]. This portion of the MHC has been termed the I 
(immune) region. It has recently been demonstrated that I 
region genes code for a series of lymphocyte alloantigens called 
la (immune-response-associated) antigens. These are found on 
B lymphocytes, macrophages, and on some T lymphocytes. 
These antigens appear to be of major significance in physiolog-
ical T cell-B cell collaboration in the production of antibody to 
thymus-dependent antigens, and in allogeneic interactions, in 
which they apparently are the major antigens responsible for 
stimulation of the mixed lymphocyte reaction (MLR) . There is 
also evidence that the H-2 complex is involved in susceptibility 
to oncogenic agents, including Gross [16,17], T ennant [18], 
Friend [19], Bittner [20], radiation leukemia [21,22], and Rous 
sarcoma [23] viruses. Certain autoimmune diseases such as 
experimental allergic encephalomyelitis [24,25] in rats and thy-
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roiditis [26] in mice are clearly linked to the major histocom-
patibility locus. The human genes coding for the major MLR 
stimulatory antigens and those coding for the ability to respond 
to at least 1 antigen lie outside of the second locus of HLA 
[27]. There is also an association between the MHC and a 
variety of human disease states; this association suggests that 
HLA-associated abnormal regulation of the immuni ty system 
may be necessary for the appeaJ'ance of several types of autoim-
mune, neoplastic, and infectious diseases [28]. 
It has been suggested that there is a higher frequency ofHLA 
heterozygotes in people over 75 Yl· of age than in young normal 
ones. This hypothesis suggests that homozygotes are more 
susceptible to diseases that shorten the life span than are 
heterozygotes [29]. Our own observations suggest that HLA-B8 
women are relatively underrepresented in the aged population 
and further that HLA-B8 women have lower levels of T-cell 
function as measured by phytohemagglutinin (PHA) responses 
[30]. Studies are under way to examine the relationship between 
T -cell function and natural killer cell activity in HLA-B8-posi-
tive and -negative individuals. We shall investigate whether the 
haplotype Al-B8 or the phenotype B8 is correlated with re-
duced longevity and abnormal regulation of the immunity 
system. The HLA-Al-B8 haplotype or the B8 phenotype has 
also been implicated repeatedly in autoimmune phenomena 
[28]. It seems logical that an altered immunologic response may 
be expressed in individuals of the same HLA class predisposed 
to autoimmune disease and a decreased life span. Such individ-
uals when exposed to different antigens may be more likely to 
produce antibodies cross-reactive to self. These antibodies when 
present concomitantly with defects in immunoregulatory func-
tion may allow the development of autoimmune disease. A 
definitive analysis of this hypothesis will be of great interest 
not only with respect to aging, but as an initial approach to 
understanding the implications of the extensive polymorphism 
at the MHC in all species. 
Armed with a general notion that the role of immunologic 
processes in aging must involve some genetically controlled 
parameters of T-cell function, one still finds it quite difficult to 
design meaningful experiments to study the problem even in 
experimental animals. T-cell-dependent mitogen responses ap-
peru·ed to offer a relatively simple test because they were 
uniformly decreased with age among mice and humans. Al-
though genetic differences were obvious, there was no consist-
ently detectable influence of t he MHC on PHA responses in 
young mice [37] or rats [38]. Aging mice, congenic for the H-2 
complex, did show some differences in mitogen responses [39] 
and some H-2 congenics differed significantly in life span 
[40,41]. Therefore, we were particularly interested to find that 
in human populations HLA-B8 women were both underrepre-
sented among the aged and tended to have lesser responses to 
PHA [29]. 
Although the PHA responses seem to be a reliable test for 
the functional presence of cell-mediated immune function, data 
from studies designed to use the PHA response as a continuous 
quantitative variable to assess relative cellulaJ· immunologic 
competence in humans cannot be validly interpreted until there 
is better information concerning reproducibility. Because cul-
ture of cells is required, variability may fluctuate within a range 
according to the variables of the assay. Reproducibility within 
a single individual can then be tested by the use of identically 
treated cryopreserved samples drawn at the same time of the 
day (because of known circadian variability) and then assayed 
simultaneously in a single experiment. 
THE IMMUNOLOGIC THEORY OF AGING 
Theories concerning the association of immunologic malfunc-
tion and aging have taken several directions. The immunologic 
theory of aging, fust clearly stated by Walford [3], was exten-
sively promulgated and developed by Burnet [31]. This theory 
states that the immunity system is essential to the maintenance 
of health and that the integrity of this system determines 
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survival. Walford further suggested that aging results from 
somatic cell variations of factors that determine self-recogni tion 
among cells. The progressive breakdown of this system results 
in the occurrence of autoimmunity and autoimmune disease. In 
our studies, the decline in vigorous immune function in man 
and mice during aging has been associated with the same 
diseases and immunologic a bnormali t ies found in humans and 
animals that lack normal T-cell immunity systems [9]. These 
types of observations led Burnet [32] to suggest that clones of ' 
cells, ordinarily forbidd en by an intact immune system, appear 
by somatic mutation and persist when immune functions be-
come defective. He concluded that this event explains the 
frequent autoimmunity observed in aging and in immunodefi-
cient humans and animals. 
On the other hand, Good and Yunis [9] interpreted these 
associations with a forbidden-antigen theory of autoimmunity, 
i.e. , argued that under several circumstances of immunodefi-
ciency, antigens that otherwise would be prohibited from en-
tering the body, or promptly elimina ted from it, are permitted 
to enter. They may then persist as infectious agents or as 
antigens that generate cross-reacting antibodies as a conse-
quence of an inefficient or ineffective immunologic response 
[9,10,33]. 
One possible immunologic theory of aging based on thymic 
involution holds that the primary events of aging are embodied 
in a genetically programmed, chronological process of declining 
function and control of immunity through the T-cell-dependent 
lymphoid system. The genetically programmed clock operates 
at a rate consistent with the median life span of the species and, 
for the longest-lived individuals or strains, may adhere to limits 
imposed by the postulate of Hayflick [34]. 
It appears that the primal'y age-related change in the im-
munity system is a decrease in the T-cell functional capacity . 
The idea that this age-associated deficiency may be important 
in pathogenesis in the aged is supported by the observation 
that old people with defective cell-mediated immunity have a 
decreased life expectancy [35]. The resulting imbalanced im-
munity system in which the host is T-cell-deficient even though 
the B cells are relatively normal may be an important factor in 
the increased appearance of autoantibody and the autoimmune 
nature of a number of diseases associated with aging, especially 
if the ordinal"ily balanced T-cell subpopulation becomes dis-
turbed, as our own studies suggest [36]. One kind of T-cell 
deficiency may be a decrease in suppressor-cell function. This 
type of event could allow autoimmune clones to arise or to be 
expressed. Conversely, loss of self-tolerance and the occurrence 
of autoimmunity could lead to the production of anti-T-cell 
autoantibodies and acceleration of the T -cell immunodeficiency 
with aging. 
DISCUSSION AND CONCLUSIONS 
Although research on the prolongation of life is only begin-
ning, promising achievements are anticipated from investiga-
tions in this du'ection. At the moment, prolongation of life far 
beyond the limits imposed by ultimate genetic determinants 
seems remote. In short, it is unlikely that mice can be given the 
life span of humans. However, identification of the genetically 
determined vulnerabilities and thus delay of the appearance of 
the diseases of aging seem promising. Thus, the possibility of 
manipulating the calculated life span by permitting all or many 
members of an inbred strain or individuals of an outbred species 
to reach the limitations of their genetic potentiality seems to be 
an approachable goal. 
Genetically superior people may live as long as 95 to 110 yr 
in vigorous good health. Arteriosclerosis, coronary m'tery dis-
ease, renal disease, cancer, autoimmunity, and infections 
shorten the life span to less than this potential. If these diseases 
of aging could be prevented or even reversed, the possibility of 
achieving much longer life with good health would be very real. 
Recent experimental observations suggest several directions in 
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which such a goal could be realistically approached, By simple 
dietary protein or caloric restriction, it has been possible in 
NZB mice and more drastically in B/ W mice to delay the 
development of a whole set of diseases similar to those that 
shorten the lives of many humans. This delay has been accom-
plished by procedures that also restore or maintain immuno-
logic vigor otherwise lost with aging. Study of t he mechanisms 
by which diet accomplishes its influence may indeed yield 
approaches with greater flexibility and greater acceptance than 
long-term caloric restriction [12]. 
In conclusion, thymic involution and cellular immune dys-
function may influence the genesis of several diseases of aging, 
but the etiology of such diseases may be related to genetically 
determined systems involving immune recognition. Dietm'y ma-
nipulation favors the influence of the thymus system in the 
genesis of diseases of aging and in the longevity of the individ-
ual. On the other hand , optimal functional longevity is geneti-
cally based and controlled by many genes thl'ough the function 
of several control systems. That some of these systems m'e 
influenced by the MHC gives us an approach for experimental 
studies on age-associated disease. 
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